Biogen Inc. (BIIB)

339.10
1.60 0.46
NASDAQ : Health Technology
Prev Close 337.54
Open 337.43
Day Low/High 335.65 / 339.24
52 Wk Low/High 249.17 / 388.67
Volume 49.28K
Avg Volume 1.30M
Exchange NASDAQ
Shares Outstanding 201.48M
Market Cap 66.57B
EPS 11.90
P/E Ratio 21.39
Div & Yield N.A. (N.A)
Target, US Bancorp, BlackRock: 'Mad Money' Lightning Round

Target, US Bancorp, BlackRock: 'Mad Money' Lightning Round

Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, US Bancorp, BlackRock and more.

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Market Loves Fintech: Cramer's 'Mad Money' Recap (Thursday 7/19/18)

Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.

5 Big Biotech Stories to Watch

5 Big Biotech Stories to Watch

The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.

2 Small Biotechs I Like in the Second Half

2 Small Biotechs I Like in the Second Half

Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.

Biogen Stock: A Long-Term Bullish Perspective

Biogen Stock: A Long-Term Bullish Perspective

After Friday's surge another look at BIIB is warranted.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen Sparks Hope on Treating Alzheimer's Disease: Everything You Must Know

Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Stocks Rise Despite Trade War Worries; Biogen Shares Soar -- ICYMI

Here's what you need to know now for Friday, July 6.

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

Video: Jim Cramer on the Jobs Report, Tariffs and Biogen

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market

Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.

Biogen Shares Soar on Positive Alzheimer's Drug Results

Biogen Shares Soar on Positive Alzheimer's Drug Results

The company's drug showed promising results versus a placebo in a Phase 2 trial.

Biogen Wins a Battle, Not the War Against Alzheimer's

Biogen Wins a Battle, Not the War Against Alzheimer's

The history of trying to cure Alzheimer's is full of mistakes and false promises.

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Biogen: Let the Situation Cool Off a Bit Before Buying

Biogen: Let the Situation Cool Off a Bit Before Buying

There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.

Biogen Rebounds 25% in 2 Months Since TheStreet Ratings Buy Recommendation

Biogen Rebounds 25% in 2 Months Since TheStreet Ratings Buy Recommendation

Since TheStreet Ratings upgrade on May 1, shares of the biotech giant have recovered strongly.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots

First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

Biogen Soars, and It May Signal a Breakout Gap to Further Gains

My longer-term price target is now $416.

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

Sarepta Shares Skyrocket on Early Results for DMD Gene Therapy

The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.

Biogen Can Do More For the Bulls

Biogen Can Do More For the Bulls

Charts suggest that shares of Biogen have farther to run.

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Biogen Takes Over #107 Spot From Nielsen Holdings

In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #107 spot from Nielsen Holdings PLC , according to ETF Channel. Below is a chart of Biogen Inc versus Nielsen Holdings PLC plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; NLSN plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.

Biogen Is Set for a Tradable Rally

Biogen Is Set for a Tradable Rally

BIIB looks like it can rally at least 10% from here.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, AMOV, AMX, ARE, BIIB, BSM, DAN, DO, FUL, GIGM, JD, NGVT, OIS, WLL Downgrades: EQT, IVAC, PTNR, WP Initiations: ICCH Read on to get TheStreet Quant Ratings' detailed report:

Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

Biogen And Neurimmune Announce Option Exercise For Alzheimer's Disease Investigational Treatment Aducanumab

Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen's Phase 3 investigational treatment for early...

TheStreet Quant Rating: B+ (Buy)